Discovery and Protein Modeling Studies of Novel Compound Mutations Causing Resistance to Multiple Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.
Asian Pacific Journal Of Cancer Prevention : Apjcp
Iqbal, Zafar Z; Absar, Muhammad M; Mahmood, Amer A; Aleem, Aamer A; Iqbal, Mudassar M; Jameel, Abid A; Akhtar, Tanveer T; Karim, Sajjad S; Rasool, Mahmood M; Mirza, Zeenat Z; Khalid, Muhammad M; Akram, Afia Muhammad AM; Sabar, Muhammad Farooq MF; Khalid, Ahmad M AM; Aljarrah, Khalid K; Iqbal, Janhangir J; Khalid, Muhammad M; Shah, Ijaz H IH; Alanazi, Nawaf N
Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib.
American Journal Of Hematology
Cortes, Jorge E JE; Khoury, Hanna J HJ; Kantarjian, Hagop M HM; Lipton, Jeff H JH; Kim, Dong-Wook DW; Schafhausen, Philippe P; Matczak, Ewa E; Leip, Eric E; Noonan, Kay K; Brümmendorf, Tim H TH; Gambacorti-Passerini, Carlo C
Characterizing of Four Common BCR-ABL Kinase Domain Mutations (T315I, Y253H, M351T and E255K) in Iranian Chronic Myelogenous Leukemia Patients With Imatinib Resistance.